Telomir Pharmaceuticals Inc (TELO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.78-10.85%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · TELO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
We’re excited to advance Telomir-Zn into our Phase 1/2 program under our active IND to test whether this approach can meaningfully improve outcomes for TNBC patients.”
Stated in 2 of 2 supplied quarters. Management reported: “The Company intends to use the net proceeds primarily to support the clinical development of Telomir-Zn, including its Phase 1/2 clinical program in advanced or metastatic triple-negative breast cancer (TNBC), as well as for working capital and general corporate purposes.” “We’re excited to advance Telomir-Zn into our Phase 1/2 program under our active IND to test whether this approach can meaningfully improve outcomes for TNBC patients.”” Net income was $-1.722 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Over the trailing year it converted 0.30x of net income into operating cash flow.
Not enough signal yet.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We’re excited to advance Telomir-Zn into our Phase 1/2 program under our active IND to test whether this approach can meaningfully improve outcomes for TNBC patients.””
“The data demonstrated meaningful improvements across a comprehensive set of endpoints in the Wilson’s disease model, and we believe the findings are consistent with the broader mechanistic profile of…”
“Our strategy is to raise capital around meaningful milestones, deploy it toward value-driving objectives and progressively de-risk the program, while remaining mindful of our existing shareholders.
Stated in a supplied disclosure. Management reported: ““We have been very deliberate about how and when we access the capital markets,” said Erez Aminov, Chairman and CEO of Telomir.” ““Our strategy is to raise capital around meaningful milestones, deploy it toward value-driving objectives and progressively de-risk the program, while remaining mindful of our existing shareholders.”
These preclinical findings provide the scientific foundation supporting advancement of Telomir-Zn toward the Company’s planned Phase 1/2 clinical trial in TNBC.
Stated in 2 of 2 supplied quarters. Management reported: “These preclinical findings provide the scientific foundation supporting advancement of Telomir-Zn toward the Company’s planned Phase 1/2 clinical trial in TNBC.” “This publication represents Telomir-Zn’s first peer-reviewed publication in Wilson’s disease and adds independently validated preclinical data across biochemical, functional, histological, and survival endpoints to the Company’s scientific package.”
“These preclinical findings provide the scientific foundation supporting advancement of Telomir-Zn toward the Company’s planned Phase 1/2 clinical trial in TNBC.”
“This publication represents Telomir-Zn’s first peer-reviewed publication in Wilson’s disease and adds independently validated preclinical data across biochemical, functional, histological, and surviv…”
Progress Telomir-Zn through Phase 1/2 clinical trials targeting advanced or metastatic triple-negative breast cancer with focus on safety, dose selection, and efficacy.
Finalize the acquisition of TELI Pharmaceuticals and integrate its assets to strengthen Telomir's pipeline and capabilities.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
27 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.